iBio, Inc.’s Post

3 years ago, I discovered BioRender, and it felt like a dream come true for someone who appreciates the visual side of things. By seamlessly blending science, art, and creativity, BioRender allows us to bring complex biological concepts to life. I'm excited to share our latest publication, where I had the opportunity to create a scientific illustration that summarizes the innovative biosensing methodologies developed for the detection of HCC (Hepatocellular Carcinoma) biomarkers. This publication highlights the potential of these advanced approaches to improve early diagnosis and monitoring of this complex disease. https://lnkd.in/dHuMTsT5 #BioRender #ScienceVisualization #CreativeScience #HCC #Biomarkers #MedicalResearch #research #KFSHRC

Heart failure – almost in the clinical phase. Further in the pipeline: 👉 lung fibrosis 👉 tumor microenvironment 👉 liver  👉 pancreas 👉 kidney and then… “We're really excited about the potential because we think this platform can be deployed for essentially any disease,” Samir Ounzain , the CEO of HAYA Therapeutics said on the new X-Health.show episode and Aleksandra Jani’s jaw dropped to the floor. The key is in the dark genome. “But you know, we need as a community, we need a paradigm shift in how we think about biology because you'd probably be surprised to hear there was a very strong conviction that 98% of the genome is junk– in academia.” And this is what we start this episode from – the fascinating history of the junk genome turning into dark genome turning into, as HAYA calls it now, regulatory genome. Hit the link in the comments to 🎧 hear about 💡 the richness of the regulatory genome 💡 its function: as a kind of software for the human body 💡 RNA therapies that are targeted, non-toxic, fast in development 💡 an absolutely new approach to drugs HAYA Therapeutics is a Swiss startup that created the world’s largest long non-coding RNA database. These RNAs play a critical function in the dark genome. They selected one of them, called Wisper, to develop a highly targeted drug to address cardiovascular disease. They are based in both Lausanne and San Diego. Thank you François Capel and Innovaud for connecting us 🙏 #biotech #heartfailure #RNA #futureofhealthcare #healthcareinnovation #swissstartups #xhealth BioAlps - Swiss Health Valley Biopôle Lausanne Buzzsprout

See the growing body of evidence that supports the role of #ergothioneine as a #longevityvitamin,' with potential wide-ranging benefits for promoting #health and #longevity, including age-related #hearinghealth! Compelling new research from the University of South Florida indicates that #Lergothioneine may slow the progression of age-related #hearingloss in a preclinical rodent model. #Ergothioneine treatment also reduced serum biomarkers related to cochlear inflammation and cell death. Despite the sample size, ergothioneine seemed to increase the #lifespan in these animals. This lifespan finding aligns with the previous study we posted about research in Japan. #wellness Read the study here ⇢ https://bit.ly/3xzzSFB

🌍 Outdated diagnostic methods for bacterial infections and certain cancers are holding back the potential for early and precise treatment in Ethiopia. But genomics offers a transformative alternative, delivering diagnostics that are faster, more accurate, and personalized to individual patient needs. At Retina Pharmaceuticals, we’re proud to be collaborating with Illumina to introduce advanced sequencing technologies and we are also excited tio announce that we are preparing to provide custom genomic libraries to Ethiopia's healthcare landscape. 🚀 This initiative is set to empower the healthcare community by addressing critical diagnostic challenges and supporting precision medicine. We invite organizations, researchers, and healthcare stakeholders to join us on this transformative journey and explore partnership opportunities that drive impactful change. 📞 For more information, please connect with Sisay Alemu at Retina Pharmaceuticals +251925528360. Let’s build a healthier future together, one genome at a time! #Genomics #HealthcareInnovation #PrecisionMedicine #Diagnostics #RetinaPharma #Illumina #EthiopianHealthcare #Partnerships #PublicHealth #EastAfricaGenomics

🔔 Only a few weeks left to get early bird discount. This is the place to be, to learn about #Cell and #genetherapy and how existing technology can be applied to solve for a rare genetic disease. If you have an interest or asset in #CysticFibrosis, #bronchiectasis, #PCD, Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) or other rare respiratory diseases, then join us on 1st October at The Francis Crick Institute. 💊 This event is for #biotech, #pharma and #investors with an interest in #rare and #orphandrugs across the continuum of development from #pipeline to #market launch. Network with leaders in #genomics, #translational medicine, #peadiatric respiratory research.

🚀 Exciting Partnership Announcement! 🚀 🔬 Boehringer Ingelheim partners with UK biotech Ochre Bio to tackle chronic liver disease. 💰 Up to $1bn partnership to develop treatments harnessing liver's regenerative capacity. 🔍 Ochre Bio's approach: - Analysing thousands of human livers to understand disease causes. - Studying RNA changes to extend lifespan of transplanted livers. - Aiming to 'nudge' liver cells to regenerate. 💡 Partnership aims to address unmet needs in advanced liver disease. 👨🔬 Boehringer sees Ochre Bio's genomics expertise as key to uncovering regenerative pathways. Exciting times ahead in liver disease treatment! 🌟 #machinelearning #biotech #drugdiscovery

Mainz BioMed (@mainzbio), a biotech firm specializing in clinical laboratory tests, is making strides in early disease detection and prevention. According to Bill Caragol, the company's CFO, their genetic and genomic tests can reveal patients' unique genetic profiles, enabling doctors to tailor treatments more effectively and ushering in an era of personalized medicine. Caragol recently shared promising data from recent trials, highlighting the potential of their tests to detect cancer and chronic conditions at an early stage. Early detection is crucial, as it allows patients to receive timely treatment and improve their chances of survival. As diagnostic technology advances, Mainz BioMed aims to save lives and reduce healthcare costs through early disease identification. Their innovative approach could revolutionize how we approach cancer and chronic condition management. #biotechnology #cancerprevention #personalmedicine

I recently presented my research on P2X7R soluble form (sP2X7R) at the third PRESTO meeting in Murcia, Spain. We discussed about the possible role of this receptor as pro-inflammatory mediator with a function in disease spreading and amplification, and possible useful biomarker in diagnostic medicine -What is PRESTO? It is an EU COST action (CA21130) that aims to booster the research on P2X receptors. These receptors have ATP as endogenous ligand and are involved in several mechanisms such as inflammation. -Why is PRESTO cool? 😎 It is a very nice opportunity to meet scientists from different countries that study your same topic. Thanks to this initiative we can exchange information and establish new collaboration like a group of friends that share a common passion and meet regularly. If you want to learn more you can follow the updates on Prestocostcomms. #PRESTO #Purines #Purinergicsignaling #ATP #COST #research

I’m excited to share the work led by Dr Nadhir Yousfi and Prof. Laurent MESNARD, to which I had the privilege of contributing. In this letter to the journal Blood, we show how nanopore sequencing can enable fast genomic testing in cases of adult thrombotic microangiopathies. We describe 18 prospective cases to illustrate the benefits of this approach: ⏱️ Rapid turn-around time: Time to genomic results reduced from the standard 3–8 weeks to less than 3 days. 🧬 Clinical-grade analytical performance: Comparable to standard-of-care short-read sequencing, and in addition, detects highly complex structural variants of complement factor H-related genes (!!). 💊 Clinical impact: Timely, targeted treatment with complement blockade might improve patient outcomes. 💵 Cost-efficiency: Faster diagnostics could also reduce healthcare costs by minimizing unnecessary treatments. This is a great example of the benefits of integrating innovative AND accessible genomic workflows into routine clinical practice, particularly in nephrology and critical care. Read the full publication here: https://lnkd.in/exCKPDWz #Genomics #PrecisionMedicine #ThromboticMicroangiopathy #TMA #NanoporeSequencing #Nephrogenomics #ONT

Advancements in lupus research are paving the way for improved patient care through precision medicine, biological therapies, biomarker discovery, and patient-centered approaches. Exploring the gut microbiome's role opens new therapeutic avenues. Collaboration among all stakeholders is key to realizing these potential breakthroughs. https://lnkd.in/duD5wnpq #LupusResearch #PrecisionMedicine #BiologicalTherapies #Biomarkers #PatientCare Dipti Gogate